Neurocrine Biosciences (NBIX) announced the completion of its acquisition of Soleno Therapeutics (SLNO), strengthening the company’s leadership in endocrinology and rare disease. As of May 18, Soleno’s common stock will no longer be listed or traded on the Nasdaq Capital Market.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Aardvark Therapeutics downgraded to Underperform from Buy at BofA
- Neurocrine price target raised to $185 from $177 at JPMorgan
- Neurocrine price target raised to $155 from $140 at Truist
- Neurocrine price target raised to $155 from $150 at Deutsche Bank
- Neurocrine treatment of Friedreich ataxia granted orphan designation